Refractory Acute Myeloid Leukemia (AML)

NewsGuard 100/100 Score

Refractory acute myeloid leukemia (AML) is a very challenging complication in the management of AML. In this condition, the disease is refractory or resistant and patients fail to achieve complete remission following initial treatment.

Most AML patients experience an absence of symptoms post initial treatment with multiple drugs. However, about 10% and 40% of AML patients do not respond to initial therapy and are thus categorized as refractory or resistant to treatment.

acute myeloid leukemiaMicroscope of acute myeloid leukemia (AML). Image Credit: Jarun Ontakrai / Shutterstock.com

Management of refractory AML

It is very stressful for patients to be diagnosed with refractory leukemia. The health care team consisting of physicians, nurses, and social workers needs to provide support to the patients and their families and encourage them to have open discussions.

Talking to other patients diagnosed with the resistant form of the condition or joining local support groups may also help. It is important to discuss a fresh treatment plan with doctors who have experience dealing with this particular form of AML. Taking part in clinical trials is an option for some patients. Patients are also advised to get a second opinion from another doctor before starting any new treatment.

The new treatment plan may involve new types of drugs that were not used during primary therapy and other drugs that are undergoing tests in clinical trials. Palliative care is crucial to help manage symptoms and side effects of treatment and thus optimize the quality of life of the patient.

New treatment plans must be carefully devised after taking into account several factors, such as the patient’s age, preference, cytogenetic findings, response to drugs, molecular profile. Therapy needs to be customized for each patient depending on their specific disease details. Some of them may not be fit for intensive chemotherapy.

Dr. Ravandi on Relapse/Refractory AML

Allogeneic stem cell transplantation

Allogeneic stem cell transplantation is a treatment option for people diagnosed with refractory AML.

This involves the transfer of stem cells from a healthy donor to the patient’s body after intensive radiation or chemotherapy. This procedure is used to treat high-risk AML patients who do not fully respond to initial treatment or patients in whom a relapse of the disease is found post previous successful treatment. It can be a risky procedure due to the high-intensity chemotherapy or radiation given prior to stem cell transplantation. Intensive radiation and chemotherapy cause severe side effects and also impair the ability to produce one’s own stem cells.

The main objective of this intensive therapy is to deactivate the immune system, thus preparing it to receive new stem cells. It reduces the possibility of graft rejection, kills the remaining cancer cells so as to prevent a recurrence of cancer, and enables an overall successful transplant.

Stem cells to be transplanted can be gathered from blood, bone marrow, or blood from the placenta or the umbilical cord. Finding a bone marrow donor is an important step in allogeneic stem cell transplantation. Siblings, if any, are usually a potential match as they share the same genes. If this is not an option, volunteer donors will need to be found using search registries. Potential donors need to undergo comprehensive blood tests and physical examination before stem cell collection to rule out any serious infectious diseases.

Adverse effects of stem cell transplant

Since the immune system of the donor is also transferred during stem cell transplant, adverse immune reactions caused by the donor cells against the patient’s body tissues are possible. This is minimized by pharmacotherapy post-transplant.

Allogeneic stem cell transplant is not advised for patients whose overall health condition is poor or older patients, because they might not be able to tolerate the intensive therapy given prior to transplant. In some older patients, the use of a low-intensity stem cell transplant may be appropriate.

References

Further Reading

Last Updated: Jan 27, 2021

Susha Cheriyedath

Written by

Susha Cheriyedath

Susha is a scientific communication professional holding a Master's degree in Biochemistry, with expertise in Microbiology, Physiology, Biotechnology, and Nutrition. After a two-year tenure as a lecturer from 2000 to 2002, where she mentored undergraduates studying Biochemistry, she transitioned into editorial roles within scientific publishing. She has accumulated nearly two decades of experience in medical communication, assuming diverse roles in research, writing, editing, and editorial management.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cheriyedath, Susha. (2021, January 27). Refractory Acute Myeloid Leukemia (AML). News-Medical. Retrieved on May 30, 2024 from https://www.news-medical.net/health/Refractory-Acute-Myeloid-Leukemia-(AML).aspx.

  • MLA

    Cheriyedath, Susha. "Refractory Acute Myeloid Leukemia (AML)". News-Medical. 30 May 2024. <https://www.news-medical.net/health/Refractory-Acute-Myeloid-Leukemia-(AML).aspx>.

  • Chicago

    Cheriyedath, Susha. "Refractory Acute Myeloid Leukemia (AML)". News-Medical. https://www.news-medical.net/health/Refractory-Acute-Myeloid-Leukemia-(AML).aspx. (accessed May 30, 2024).

  • Harvard

    Cheriyedath, Susha. 2021. Refractory Acute Myeloid Leukemia (AML). News-Medical, viewed 30 May 2024, https://www.news-medical.net/health/Refractory-Acute-Myeloid-Leukemia-(AML).aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel approach improves CAR T-cell therapy efficacy against acute myeloid leukemia